Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Nine out of ten U.S. neurologists have Aduhelm efficacy doubts

By Brian Buntz | May 12, 2022

AduhelmA recent physician survey found that 89% of neurologists in the U.S. have concerns about the efficacy of the controversial Alzheimer’s drug Aduhelm (aducanumab) from Biogen (Nasdaq:BIIB) and Eisai Co. (TYO:4523). Nearly as many — 87% — were concerned about the drug’s safety profile.

The survey from the physician social media network Sermo (New York City) asked more than 50 neurologists about their view of the drug, which has failed to find widespread use, generating just $3 million in 2021. Only 11% of the neurologists surveyed reported prescribing the drug.

Despite low uptake, many patients are aware of the drug. A total of 62% of the surveyed neurologists reported that at least one patient had asked them about Aduhelm.

“Despite lively and ongoing debate among academic research experts, limited attention has been paid to the views of practicing neurologists on biomarker-based accelerated approvals for Alzheimer’s disease,” said Dr. Murali Doraiswamy, professor of psychiatry and professor of medicine at Duke University School of Medicine, and an advisor to Sermo. “To my knowledge, this is the first survey to seek the opinions of neurologists and GPs on this topic.”

Although the survey sample was small, “the findings are quite compelling,” Doraiswamy added. “The vast majority of practicing GPs and neurologists remain unconvinced of the efficacy and safety of Aduhelm. Even the best innovation will fail if end users are not open to it.”

Aduhelm has faced an array of challenges since it was FDA-approved in June 2021. Recently, Medicare decided to limit Aduhelm’s coverage of the drug to clinical trial participants, and other payers, including the Department of Veteran Affairs, have also not warmed to it. Biogen scrapped an attempt to win market authorization for the drug in the EU while cutting the U.S. price of the drug in half in December. Early this month, the company’s CEO Michel Vounatsos announced he would leave the company, while the company’s former head of R&D, Dr. Alfred Sandrock, departed last year.

Aduhelm is unlikely to be the last targeting amyloid or tau in the brain of Alzheimer’s patients.

Earlier this month, Biogen partner Eisai completed its rolling FDA submission of a Biologics License Application (BLA) for anti-amyloid agent lecanemab (BAN2401), a potential antibody treatment for treating mild Alzheimer’s disease and mild cognitive impairment stemming from the condition.

Biogen also continues to recruit Alzheimer’s for its Phase 4 ICARE AD-US Aduhelm trial, which is investigating the safety and effectiveness of Aduhelm.

In any event, more data are likely needed to resolve neurologists’ concerns about Aduhlem and other similar future drugs. “Additional research and education should be a high priority for the field and companies developing similar drugs,” Doraiswamy concluded.


Filed Under: Neurological Disease
Tagged With: Aducanumab, Aduhelm, Alzheimer’s, amyloid, Biogen, Eisai
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
Randy Bateman, MD, talks with research technician Olatayo Ajenifuja about Alzheimer’s Disease research in his lab on January 4, 2024, in the Neuroscience Research Building. MATT MILLER/WASHINGTON UNIVERSITY SCHOOL OF MEDICINE
Discontinued Alzheimer’s drug shows surprising long-term promise in genetic form of the disease
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE